Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 0.77 |
| ▸ | HTR1A | P08908 | 3/20 | 0.77 |
| ▸ | HTR7 | P34969 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 1/20 | 0.77 |
| ▸ | HTR6 | P50406 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24892717 | 0.92 | DRD2 (0.85) | DRD2HTR2AHTR1AHTR7DRD3 | |
| SCHEMBL20512920 | 0.87 | DRD2 (1.00) | DRD2HTR2AHTR1AHTR7DRD3 | |
| SCHEMBL20512968 | 0.86 | DRD2 (1.00) | DRD2HTR2AHTR1AHTR7DRD3 | |
| SCHEMBL23953302 | 0.83 | DRD2 (0.91) | DRD2HTR2AHTR1AHTR7DRD3 | |
| SCHEMBL1545448 | 0.82 | HTR2A (0.77) | DRD2HTR2AHTR1ADRD3HTR6 | |
| SCHEMBL15703012 | 0.81 | KCNH2 (0.74) | DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL24892667 | 0.80 | DRD2 (0.67) | DRD2HTR2AHTR1AHTR7DRD3 | |
| SCHEMBL23409206 | 0.80 | HTR6 (0.68) | DRD2HTR2AHTR1ADRD3HTR6 | |
| SCHEMBL7974099 | 0.80 | HTR2A (0.68) | DRD2HTR2AHTR1ADRD3 | |
| SCHEMBL7974089 | 0.80 | HTR2A (0.68) | DRD2HTR2AHTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3381915-B1 | LACTAM COMPOUND DERIVATIVE AND APPLICATION THEREOF | NHWA PHARMA CORP (CN) | 2023-01-18 | — | — | EP | disclosed |
| CN-112851656-B | Lactam compound derivative and application thereof | 江苏恩华药业股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-112851656-A | Lactam compound derivative and application thereof | 江苏恩华药业股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-108290880-B | Lactam compound derivative and application thereof | 江苏恩华药业股份有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20180327397-A1 | LACTAM COMPOUND DERIVATIVE AND APPLICATION THEREOF | NHWA PHARMA. CORPORATION (CN) | 2018-11-15 | — | — | US | disclosed |
| EP-3381915-A1 | LACTAM COMPOUND DERIVATIVE AND APPLICATION THEREOF | NHWA Pharma Corporation (CN) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327397-A1 | LACTAM COMPOUND DERIVATIVE AND APPLICATION THEREOF | BACE1, QPCT, PSENEN | DRD2 56/4885HTR2A 1828/4885HTR1A 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.